These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 14561942)

  • 1. Endothelin in neurohormonal activation in heart failure.
    Boerrigter G; Burnett JC
    Coron Artery Dis; 2003 Nov; 14(7):495-500. PubMed ID: 14561942
    [No Abstract]   [Full Text] [Related]  

  • 2. [Endothelin receptor blockers--one more agent for the treatment of pulmonary hypertension].
    Minushkina LO; Zateĭshchikov DA; Sidorenko BA
    Kardiologiia; 2003; 43(9):67-71. PubMed ID: 14593372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tezosentan, another selective selection for pulmonary hypertension, or not?
    Lorts A; Shanley TP
    Pediatr Crit Care Med; 2004 Nov; 5(6):586-8. PubMed ID: 15540040
    [No Abstract]   [Full Text] [Related]  

  • 4. Enrasentan, an antagonist of endothelin receptors.
    Cosenzi A
    Cardiovasc Drug Rev; 2003; 21(1):1-16. PubMed ID: 12595914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments in heart failure: role of endothelin and the use of endothelin receptor antagonists.
    Suresh DP; Lamba S; Abraham WT
    J Card Fail; 2000 Dec; 6(4):359-68. PubMed ID: 11145761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin receptor blockade in congestive heart failure.
    Cheng TO
    Circulation; 2001 Oct; 104(18):E96. PubMed ID: 11684644
    [No Abstract]   [Full Text] [Related]  

  • 7. The neurohormonal paradigm: have we gone too far?
    Gottlieb SS
    J Am Coll Cardiol; 2003 May; 41(9):1458-9. PubMed ID: 12742281
    [No Abstract]   [Full Text] [Related]  

  • 8. Is there a role for endothelin in the natural history of heart failure?
    Cohn JN
    Circulation; 1996 Aug; 94(4):604-6. PubMed ID: 8772676
    [No Abstract]   [Full Text] [Related]  

  • 9. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure.
    Schalcher C; Cotter G; Reisin L; Bertel O; Kobrin I; Guyene TT; Kiowski W
    Am Heart J; 2001 Aug; 142(2):340-9. PubMed ID: 11479476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin mediates the altered renal hemodynamics associated with experimental congestive heart failure.
    Qiu C; Ding SS; Hess P; Clozel JP; Clozel M
    J Cardiovasc Pharmacol; 2001 Aug; 38(2):317-24. PubMed ID: 11483881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Will endothelin receptor antagonists have a role in heart failure?
    Spieker LE; Lüscher TF
    Med Clin North Am; 2003 Mar; 87(2):459-74. PubMed ID: 12693734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelin in cardiopulmonary disease: factor paracrine vs neurohumoral.
    Stewart DJ
    Eur Heart J; 1993 Nov; 14 Suppl I():48-54. PubMed ID: 7904941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy?
    Teerlink JR
    J Card Fail; 2002 Jun; 8(3):124-7. PubMed ID: 12140803
    [No Abstract]   [Full Text] [Related]  

  • 14. Glibenclamide reveals role for endothelin in hypoxia-induced vasoconstriction in rat intrapulmonary arteries.
    López-Valverde V; Andersen CU; Laursen BE; Mulvany MJ; Simonsen U
    J Cardiovasc Pharmacol; 2005 Oct; 46(4):422-9. PubMed ID: 16160592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure.
    Cotter G; Kaluski E; Stangl K; Pacher R; Richter C; Milo-Cotter O; Perchenet L; Kobrin I; Kaplan S; Rainisio M; Frey A; Neuhart E; Vered Z; Dingemanse J; Torre-Amione G
    Eur J Heart Fail; 2004 Aug; 6(5):601-9. PubMed ID: 15302008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
    McMurray JJ; Teerlink JR; Cotter G; Bourge RC; Cleland JG; Jondeau G; Krum H; Metra M; O'Connor CM; Parker JD; Torre-Amione G; van Veldhuisen DJ; Lewsey J; Frey A; Rainisio M; Kobrin I;
    JAMA; 2007 Nov; 298(17):2009-19. PubMed ID: 17986694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of tezosentan, a non-selective endothelin receptor antagonist, on shear stress-induced changes in arterial diameter of the anaesthetized dog.
    Markos F; Hennessy BA; Fitzpatrick M; O'Sullivan J; Snow HM
    J Physiol; 2002 Nov; 544(3):913-8. PubMed ID: 12411533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin shock.
    Konrad D; Oldner A; Rossi P; Wanecek M; Rudehill A; Weitzberg E
    Crit Care Med; 2004 May; 32(5):1192-9. PubMed ID: 15190972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of new medical treatments for acute decompensated heart failure.
    Teerlink JR
    Heart Fail Monit; 2002; 2(4):129-37. PubMed ID: 12634887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enrasetan. SB 217242.
    Drugs R D; 1999 Jul; 2(1):24-5. PubMed ID: 10610275
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.